Igyxos Biotherapeutics

Executive Summary

Igyxos Biotherapeutics is a Paris-based biotechnology company founded in 2020, pioneering monoclonal antibody-based therapeutics to treat infertility in both men and women. The company's platform aims to enhance the activity of key reproductive hormones, addressing a significant unmet need in reproductive health. Currently in the pre-clinical stage, Igyxos is developing novel antibody candidates that could offer improved efficacy and safety over existing hormone-based treatments. The privately-held company has not disclosed total funding or valuation, but its innovative approach positions it for potential partnerships or further investment as it advances toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND-enabling studies completion60% success
• H1 2027Series A funding announcement50% success
• TBDStrategic partnership with fertility clinic network40% success